前往主要內容區間
掛號頁面

血液暨腫瘤科

  • 江翊豪醫師相片

    江翊豪

    主治醫師

    血液暨腫瘤科 :
    台北門診掛號  淡水門診掛號

    江翊豪醫師本頁二維碼

  • 現職

      馬偕紀念醫院 細胞與再生醫療中心主任
      馬偕紀念醫院 資深主治醫師

    主要學歷

      中國醫藥大學 醫學士


    主要經歷

      美國賓夕法尼亞大學(University of Pennsylvania)細胞免疫治療中心 Abramson Cancer Center, Carl H. June Lab 國際研究學者
      癌症安寧緩和專科醫師
      腫瘤內科專科醫師
      血液病專科醫師
      內科專科醫師

    其他相關

      <學會會員>
      台灣內科醫學會
      中華民國癌症醫學會
      中華民國血液病學會
      台灣安寧緩和醫學會
      <證書>
      醫師證書
      內科專科醫師證書
      中華民國血液病專科醫師證書
      中華民國腫瘤內科專科醫師證書

主治項目或專長

研究領域: Chimeric antigen receptor T-cell therapy嵌合抗原受體T細胞療法。



腫瘤免疫治療、胃腸道癌症(食道癌、胃癌、膽道癌、胰臟癌、大腸直腸癌)、黑色素瘤、肺癌乳癌,轉移癌症 、血液病、貧血、白血病、淋巴瘤、泌尿道癌症及其它各類惡性腫瘤。


論文研究

  1. Yi-Hao Chiang*, Ching-Ting Lien, Wen-Hao Su, Tsung-Yu Yen, Yu-Jen Chen, Yuen-Liang Lai, Ken-Hong Lim, Kun-Yao Dai, Hsin-Pei Chung, Chia-Yen Hung and Yi-Shing Leu. Effectiveness of fentanyl buccal soluble film in cancer patients with inadequate breakthrough pain control. BMC Palliative Care. 2024 Jun 14;23(1):150.

  2. Yi-Hao Chiang*, Ken-Hong Lim, Yi-Wei Chen. CAR T-Cell Therapy for EBV-Associated Hematopoietic Malignancies. International Journal of Gerontology. 2023;17(2):88-91.

  3. Patel RP, Ghilardi G, Zhang Y, Chiang YH*, Xie W, Guruprasad P, Kim KH, Chun I, Angelos MG, Pajarillo R, Hong SJ, Lee YG, Shestova O, Shaw C, Cohen I, Gupta A, Vu T, Qian D, Yang S, Nimmagadda       A, Snook AE, Siciliano N, Rotolo A, Inamdar A, Harris J, Ugwuanyi O, Wang M, Carturan A, Paruzzo L, Chen L, Ballard HJ, Blanchard T, Xu C, Abdel-Mohsen M, Gabunia K, Wysocka M, Linette GP, Carreno B, Barrett DM, Teachey DT, Posey AD, Powell DJ Jr, Sauter CT, Pileri S, Pillai V, Scholler J, Rook AH, Schuster SJ, Barta SK, Porazzi P, Ruella M. CD5 deletion enhances the antitumor activity of adoptive T cell therapies. Science Immunology 2024 Jul 19;Vol9, NO.97.

  4.  Chang YC, Chiang YH*, Hsu K, Chuang CK, Kao CW, Chang YF, Chang MC, Lim KH, Cheng HI, Hsu YN, Chen CG. Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors  in patients with chronic myeloid leukemia. Blood Cancer Journal 2021 Nov 16; 11(11): 182.

  5. Lim KH, Wu JN, Huang TY, Jhuang JY, Chang YC, Lin HC, Chiang YH*, Su YW, Chen GS, Chang YF, Lim J. Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell      DNA sequencing. Blood Adv. 2021 Mar 23; 5(6): 1733-36.

  6. Cheng CC, Chou KF, Wu CW, Su NW, Peng CL, Su YW, Chang J, Ho AS, Lin HC, Chen CG, Yang BL, Chang YC, Chiang YH*, Lim KH, Chang YF. EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer. Lung Cancer. 2018 Feb; 116: 80-89. 

  7. Chiang YH*, Chang YC, Lin HC, Huang L, Cheng CC, Wang WT, Cheng HI, Su NW, Chen CG, Lin J, Chang YF, Chang MC, Hsieh RK, Chou WC, Lim KH, Kuo YY. Germline variations at JAK2, TERT,HBS1L-MYB and MECOM and the risk of myeloproliferative neoplasms in Taiwanese population. Oncotarget. 2017 Jul 12.
  8. Lim KH, Chen CG, Chang YC, Chiang YH*, Kao CW, Wang WT, Chang CY, Huang L, Lin CS, Cheng CC, Cheng HI, Su NW, Lin J, Chang YF, Chang MC, Hsieh RK, Lin HC, Kuo YY. Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia. Oncotarget. 2017 May 16; 8(20):32476-32491.
  9. mChang YC, Lin HC, Chiang YH*, Chen CG, Huang L, Wang WT, Cheng CC, Lin J, Chang YF, Chang MC, Hsieh RK, Chen SJ, Lim KH, Kuo YY. Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms. Med Oncol. 2017 May; 34(5):83.
  10. Ken-Hong Lim, Yu-Cheng Chang, Yi-Hao Chiang*, Huan-Chau Lin, Chiao-Yi Chang, Ching-Sung Lin, Ling Huang, Wei-Ting Wang, Caleb Gon-Shen Chen, Wen-Chien Chou, and Yuan-Yeh Kuo. Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish. Blood Cancer J. 2016 Oct 7;6(10):e481. doi: 10.1038/bcj.2016.83.
  11. K-H Lim, Y-C Chang, C Gon-Shen Chen, H-C Lin, W-T Wang, Y-H Chiang*, H-I Cheng, N-W Su, J Lin, Y-F Chang, M-C Chang, R-K Hsieh, Y-Y Kuo and W-C Chou. Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis. Blood Cancer Journal. 2015, Mar; 5, e295.
  12. Ken-Hong Lim, Huan-Chau Lin, Yi-Hao Chiang* et al. Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis. Clin Chim Acta 2015 Feb 15;440:133-9.
  13. Ken-Hong Lim, Huan-Chau Lin, Yi-Hao Chiang* et al. Calr Mutations in Essential Thrombocythemia: Frequency, Clinical Correlation and Screening By High-Resolution Melting Analysis. December 6, 2014; Blood: 124 (21).
  14. Huan-Chau Lin, Ken-Hong Lim, Yi-Hao Chiang* et al. The Role Of tet2 DNA Methylcytosine Dioxygenase In Zebrafish Early Hematopoiesis. November 15, 2013; Blood: 122 (21).
  15. Huan-Chau Lin, Caleb Gon-Shen Chen, Yi-Hao Chiang* et al. JAK2 V617F Mutation in Adult Taiwanese Patients with Essential Thrombocythemia: More Prevalent in Old Patients and Correlated with Higher Hemoglobin Level and Higher Leukocyte Count. International Journal of Gerontology 2013, 40-44.
  16. Yi-Hao Chiang*, Yi-Fang Chang, Ruey-Kuen Hsieh et al. Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype. Asia-Pac J Clin Oncol 2012; 8: 330–336.
  17. Yi-Hao Chiang*, Ming-Chih Chang, Chi-Kuan Chen et al. Debulking Surgery May Provide Long-term Survival for Adrenal Cortical Carcinoma with Lung Metastasis. J. Cancer Res. Pract. 27(1),19-24, 2011.